Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224747 | 0.82 | POLB (1.00) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL15215659 | 0.76 | POLB (0.72) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL1667129 | 0.75 | KDM4E (0.75) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL18354995 | 0.75 | KDM4E (1.00) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL14459525 | 0.75 | POLB (0.70) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL1104955 | 0.74 | SMN1; SMN2 (0.59) | LMNAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15986425 | 0.74 | KDM4E (0.70) | POLBKDM4ELMNAALDH1A1KMT2A | |
| Sulfapyridine SCHEMBL44219 | 0.73 | SMN1; SMN2 (1.00) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL8067195 | 0.73 | KDM4E (0.71) | POLBKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL13962914 | 0.73 | ALDH1A1 (0.74) | POLBKDM4ELMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | POLB 3499/4885KDM4E 4039/4885LMNA 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.